IMAX CORP

(a)None.

(b)None.

(c)Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements.

On May 19, 2026, Richard Gelfond, the CEO, entered into a Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K under the Exchange Act (“Item 408”) and such arrangement, the “Gelfond Plan”) for the exercise of 356,757 of stock options granted in June 2016 (the “Options”) and sale of up to 356,757 common shares underlying the Options. The Options have a 10-year expiry and are due to expire on January 3, 2027. Sales under this Gelfond Plan, which was previously disclosed in a Company subsidiary filing, may commence on August 18, 2026, after the completion of the required cooling off period under Rule 10b5-1. The Gelfond Plan will terminate on December 31, 2026, or earlier if all shares underlying the Options have been sold. This trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).

On June 26, 2026, Natasha Fernandes, the Company’s Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement (as defined in Item 408) and such arrangement, the “Fernandes Plan”) for the sale of up to 30,000 common shares of the Company. Sales under the Fernandes Plan may commence on September 24, 2026, after the completion of the required cooling off period under Rule 10b5-1. The Fernandes Plan will terminate on March 1, 2027, or earlier if all shares under the Fernandes Plan have been sold. This trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).

No other Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as defined in Item 408) were adopted or terminated by any directors or officers of the Company during the second quarter of 2026.